Dr. Steven Green, M.D
NPI: 1053792374
Total Payments
$13,842
2024 Payments
$276.61
Companies
12
Transactions
24
Medicare Patients
340
Medicare Billing
$52,084
Payment Breakdown by Category
Consulting$10,125 (73.1%)
Travel$2,086 (15.1%)
Food & Beverage$1,129 (8.2%)
Education$277.00 (2.0%)
Research$225.11 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,125 | 3 | 73.1% |
| Travel and Lodging | $2,086 | 5 | 15.1% |
| Food and Beverage | $1,129 | 12 | 8.2% |
| Education | $277.00 | 3 | 2.0% |
| Unspecified | $225.11 | 1 | 1.6% |
Payments by Type
General
$13,617
23 transactions
Research
$225.11
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $9,846 | 5 | $0 (2023) |
| CTI BioPharma Corp. | $2,719 | 7 | $0 (2023) |
| Stemline Therapeutics Inc. | $225.11 | 1 | $0 (2024) |
| PharmaEssentia USA Corporation | $200.94 | 3 | $0 (2024) |
| Celgene Corporation | $125.00 | 1 | $0 (2021) |
| Gilead Sciences, Inc. | $125.00 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $110.50 | 1 | $0 (2020) |
| Agios Pharmaceuticals, Inc. | $108.23 | 1 | $0 (2019) |
| Adaptive Biotechnologies Corporation | $105.44 | 1 | $0 (2020) |
| Incyte Corporation | $99.00 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $276.61 | 2 | Stemline Therapeutics Inc. ($225.11) |
| 2023 | $10,137 | 9 | GlaxoSmithKline, LLC. ($9,846) |
| 2022 | $2,782 | 7 | CTI BioPharma Corp. ($2,657) |
| 2021 | $125.00 | 1 | Celgene Corporation ($125.00) |
| 2020 | $314.94 | 3 | AstraZeneca Pharmaceuticals LP ($110.50) |
| 2019 | $108.23 | 1 | Agios Pharmaceuticals, Inc. ($108.23) |
| 2018 | $99.00 | 1 | Janssen Biotech, Inc. ($99.00) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | — | In-kind items and services | $225.11 | Research |
| Study: STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY • Category: Oncology | ||||||
| 10/02/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $51.50 | General |
| Category: Oncology | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 11/01/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $110.73 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 10/11/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $667.78 | General |
| 10/11/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $667.78 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Oncology | ||||||
| 09/06/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $61.95 | General |
| Category: Hematology | ||||||
| 07/24/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.00 | General |
| 02/23/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 12/10/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/26/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| Category: Hematology | ||||||
| 10/26/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Travel and Lodging | Cash or cash equivalent | $312.17 | General |
| Category: Hematology | ||||||
| 10/26/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Travel and Lodging | Cash or cash equivalent | $230.63 | General |
| Category: Hematology | ||||||
| 10/26/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Travel and Lodging | In-kind items and services | $207.20 | General |
| Category: Hematology | ||||||
| 10/26/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $158.13 | General |
| Category: Hematology | ||||||
| 10/26/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Hematology | ||||||
| 03/03/2021 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 12/09/2020 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $105.44 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 07/30/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $110.50 | General |
| Category: Oncology | ||||||
| 07/27/2020 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.00 | General |
| 02/10/2019 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $108.23 | General |
| Category: ONCOLOGY | ||||||
| 08/31/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | Stemline Therapeutics Inc. | $225.11 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 79 | 160 | $42,671 | $9,574 |
| 2022 | 8 | 185 | 400 | $114,851 | $26,564 |
| 2021 | 4 | 76 | 202 | $67,520 | $15,946 |
Total Patients
340
Total Services
762
Medicare Billing
$52,084
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 66 | $20,310 | $3,996 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 47 | $13,091 | $3,310 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 29 | 47 | $9,270 | $2,269 | 24.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 38 | 150 | $44,370 | $8,263 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 35 | 58 | $21,918 | $5,991 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 67 | $17,958 | $5,028 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 37 | $13,420 | $2,937 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $6,642 | $1,720 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 22 | $4,171 | $1,136 | 27.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 29 | $5,121 | $868.93 | 17.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 15 | 25 | $1,251 | $620.82 | 49.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 106 | $30,316 | $5,947 | 19.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 39 | $14,508 | $4,499 | 31.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 43 | $15,136 | $3,467 | 22.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $7,560 | $2,034 | 26.9% |
About Dr. Steven Green, M.D
Dr. Steven Green, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2015. The National Provider Identifier (NPI) number assigned to this provider is 1053792374.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Green, M.D has received a total of $13,842 in payments from pharmaceutical and medical device companies, with $276.61 received in 2024. These payments were reported across 24 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($10,125).
As a Medicare-enrolled provider, Green has provided services to 340 Medicare beneficiaries, totaling 762 services with total Medicare billing of $52,084. Data is available for 3 years (2021–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Internal Medicine
- Location Buffalo, NY
- Active Since 06/11/2015
- Last Updated 05/05/2021
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1053792374
Products in Payments
- Vonjo (Drug) $2,719
- OJJAARA (Drug) $778.51
- ELZONRIS (Drug) $225.11
- BESREMI (Drug) $200.94
- ONUREG (Drug) $125.00
- LYNPARZA (Drug) $110.50
- TIBSOVO (Drug) $108.23
- clonoSEQ (Device) $105.44
- IMBRUVICA (Drug) $99.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Buffalo
Sandra Sieminski, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $64,808
Student in an Organized Health Care Education/Training Program $64,808
Carter Lindborg, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $40,328
Student in an Organized Health Care Education/Training Program $40,328
Dr. Thomas Suchy, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $31,872
Student in an Organized Health Care Education/Training Program $31,872
Paola Ghione, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $20,368
Student in an Organized Health Care Education/Training Program $20,368
Vincent Croglio, Do, DO
Student in an Organized Health Care Education/Training Program — Payments: $15,454
Student in an Organized Health Care Education/Training Program $15,454
Ashish Bhatia, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $13,619
Student in an Organized Health Care Education/Training Program $13,619